Drawing for NEPHROCLOUD

USPTO serial 79435264

NEPHROCLOUD

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
REEVES, APRIL ELIZABETH
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with NEPHROCLOUD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Elizabeth Lee D'Amore

Elizabeth Lee D'Amore Lucas & Mercanti, LLP100 South Jefferson RoadSuite 202Whippany, NJ 07981

Goods and services

ClassDescriptionStatusFirst use
009Downloadable graphical user interface software for aggregating, integrating, and analyzing clinical, analytical, and imaging data in the field of kidney disease and disorders, and for visualizing patient-specific nephrological parameters, and supporting clinical decision-making by healthcare professionals; Downloadable interactive computer software for aggregating, integrating, and analyzing clinical, analytical, and imaging data in the field of kidney disease and disorders, and for visualizing patient-specific specific nephrological parameters, and supporting clinical decision-making by healthcare professionals; Software as a Medical Device (SaMD), downloadable, for analyzing clinical, analytical, and imaging data relating to patient specific nephrological parameters; all the foregoing for use in hospital and clinical treatment settings, and not for use in medical practice administration, software for patient portals, patient communications, medical billing, appointment scheduling, marketing, practice management, revenue cycle management, medication management, or administrative functions for healthcare providersACTIVE—
042Software as a Service (SAAS) services featuring software for aggregating, integrating and analyzing clinical, analytical, and imaging data in the field of kidney disease and disorders, and for visualizing and prioritizing patient specific nephrological parameters to support clinical evaluation and medical decision-making by healthcare professionals; software as a service (SaaS) services featuring software for using machine learning, deep learning and deep neural networks for aggregating, integrating, and analyzing clinical, analytical, and imaging data in the field of kidney disease and disorders, and for visualizing and prioritizing patient specific nephrological parameters to support clinical evaluation and medical decision-making by healthcare professionals; providing temporary use of online non-downloadable computer software for generating clinical decision-support outputs and audit information based on nephrological parameters; all the foregoing for use in hospital and clinical treatment settings, and not for use in medical practice administration, software for patient portals, patient communications, medical billing, appointment scheduling, marketing, practice management, revenue cycle management, medication management, or administrative functions for healthcare providersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 13, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 13, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 8, 2026GPNXNOTIFICATION PROCESSED BY IB—
Oct 7, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 23, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 23, 2026OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Sep 13, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 13, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 13, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Sep 13, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 13, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 14, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 14, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 14, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 5, 2026RFNTREFUSAL PROCESSED BY IB—
Jan 17, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 17, 2026RFRRREFUSAL PROCESSED BY MPU—
Dec 11, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 10, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 3, 2025DOCKASSIGNED TO EXAMINER—
Oct 25, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 25, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 23, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance